UTMB develops a universal vaccine platform that’s cheaper and shelf stable
Researchers at The University of Texas Medical Branch at Galveston have developed a less expensive way to produce vaccines that cuts the cost of vaccine production and storage by 80 percent without decreasing safety or effectiveness. The findings are currently available in EBioMedicine.
Vaccines are the most effective way to prevent and eradicate infectious diseases. Currently, many vaccines have to be manufactured in cell culture or eggs, which is expensive and carries the risk of contaminations. In addition, most vaccines must be kept refrigerated during the transportation from manufacturers to health care clinics. In tropical and subtropical regions, such cold storage requirements could contribute to more than 80 percent of the vaccine cost.
“The ability to eliminate cell culture or eggs and cold storage will change the process of vaccine development,” said UTMB’s Pei-Yong Shi, professor in the department of biochemistry and molecular biology. “Importantly, this vaccine technology could potentially serve as a universal platform for development of live-attenuated vaccines for many viral pathogens.”
To achieve these goals, the UTMB team engineered a live-attenuated Zika vaccine in the DNA form. Once the DNA is delivered into our body, it launches the vaccine in our cells, leading to antibody production and other protective immunity. With this production method, there is no need to manufacture the vaccine in cell culture or eggs at factories. Because DNA molecules are shelf stable, the vaccine will not expire at warm temperatures and could be stockpiled at room temperature for years.
Using UTMB’s Zika vaccine as a model, the research group showed that the DNA platform worked very efficiently in mice. After a single low dose, the DNA vaccine protected mice from Zika virus infection, mother-to-fetus transmission during pregnancy and male reproductive tract infection and damage.
“This is the first study to demonstrate that, after a single low dose, a DNA vaccine could induce saturated protective immunity,” Shi said. “We will continue testing this promising Zika vaccine platform and then apply the platform to other viruses.”
The Latest on: Vaccine production
via Google News
The Latest on: Vaccine production
- New cholera vaccine to get six times cheaperon June 26, 2019 at 11:52 am
uses just one component instead of three or five used by the other three vaccines in the market, optimising the processes and reducing the cost of production. And, the phase two trials have shows that ... […]
- Prophylactic Human Vaccine Market Surge in Demand from Pharma Industry to Boost Growth By 2026on June 26, 2019 at 8:34 am
This RNActive vaccine technology enables production of safe, efficacious, and cost-effective vaccines that are protected against elevated temperature as well as inadvertent freezing. Get The Inside ... […]
- Rabies vaccine: Kerala responds to Karnataka SOSon June 25, 2019 at 8:21 pm
Karnataka, which faced a shortage of the vaccine, had written to Kerala ... We called tenders thrice, but manufacturers had cited lack of production capacity as the reason for not participating. ... […]
- Faulty vaccine makers to face heavier penaltyon June 25, 2019 at 6:48 pm
They also face revocation of production licenses, the draft says. The draft also stipulates a fine of up to 30 times the value of the produced or sold substandard vaccines, compared with a fine of up ... […]
- China considers tough law against faulty vaccineson June 25, 2019 at 5:51 pm
from vaccine development to production, distribution and vaccination. Specialized inspection teams of pharmaceutical professionals will be established at the central and provincial levels to ... […]
- Experts reveal best time to get the influenza vaccineon June 25, 2019 at 2:29 pm
antibody production is not as strong, and the level of protection is lower,” the report said. Experts say getting an annual flu shot is the best way to avoid the flu. A record 613,000 flu vaccines ... […]
- Pepscan Produces Clinical Peptides for Innovative Personalized Cancer Vaccine Trialon June 25, 2019 at 5:41 am
LELYSTAD, Netherlands, June 25, 2019 /PRNewswire/ -- Pepscan has positioned itself as a critical partner in a collaborative clinical trial with personalized anti-cancer vaccines. In this trial, ... […]
- Legislators discuss heavier punishments for vaccine crimeson June 25, 2019 at 1:00 am
China's top legislature is considering imposing heavier penalties on the production and sale of fake or substandard vaccines, Xinhua reports.The draft vaccine administration law was submitted for ... […]
- Zika Virus Vaccines Market Will Reflect Significant Growth Prospects during 2019 to 2026on June 23, 2019 at 11:39 pm
This study presents the Zika Virus Vaccines production, revenue, market share and growth rate for each key company, and also covers the breakdown data (production, consumption, revenue and market ... […]
via Bing News